Bogart Wealth LLC Raises Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Bogart Wealth LLC raised its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,805 shares of the pharmaceutical company’s stock after purchasing an additional 1,501 shares during the period. Bogart Wealth LLC’s holdings in Vertex Pharmaceuticals were worth $7,245,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also added to or reduced their stakes in the company. abrdn plc lifted its holdings in shares of Vertex Pharmaceuticals by 196.0% during the 4th quarter. abrdn plc now owns 581,018 shares of the pharmaceutical company’s stock valued at $236,410,000 after purchasing an additional 384,730 shares during the last quarter. BSN CAPITAL PARTNERS Ltd acquired a new stake in Vertex Pharmaceuticals in the fourth quarter worth about $81,378,000. Jennison Associates LLC boosted its holdings in Vertex Pharmaceuticals by 3.9% in the fourth quarter. Jennison Associates LLC now owns 3,944,913 shares of the pharmaceutical company’s stock worth $1,605,146,000 after acquiring an additional 147,248 shares in the last quarter. Northern Trust Corp grew its stake in shares of Vertex Pharmaceuticals by 4.9% during the third quarter. Northern Trust Corp now owns 2,813,563 shares of the pharmaceutical company’s stock worth $978,388,000 after acquiring an additional 131,539 shares during the last quarter. Finally, International Assets Investment Management LLC raised its position in shares of Vertex Pharmaceuticals by 21,750.1% in the 4th quarter. International Assets Investment Management LLC now owns 115,150 shares of the pharmaceutical company’s stock valued at $46,853,000 after purchasing an additional 114,623 shares during the last quarter. 90.96% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other news, COO Stuart A. Arbuckle sold 4,295 shares of Vertex Pharmaceuticals stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total value of $1,804,930.80. Following the sale, the chief operating officer now directly owns 75,718 shares of the company’s stock, valued at $31,819,732.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Chairman Jeffrey M. Leiden sold 2,656 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $419.51, for a total transaction of $1,114,218.56. Following the completion of the sale, the chairman now owns 27,644 shares of the company’s stock, valued at approximately $11,596,934.44. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, COO Stuart A. Arbuckle sold 4,295 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the completion of the transaction, the chief operating officer now directly owns 75,718 shares in the company, valued at $31,819,732.32. The disclosure for this sale can be found here. In the last three months, insiders sold 12,381 shares of company stock worth $5,203,249. Corporate insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Price Performance

NASDAQ VRTX traded down $1.24 on Thursday, hitting $417.58. The company had a trading volume of 89,881 shares, compared to its average volume of 1,221,820. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.78. The company’s fifty day moving average price is $408.02 and its 200-day moving average price is $400.75. The company has a market capitalization of $107.93 billion, a PE ratio of 30.15, a PEG ratio of 1.89 and a beta of 0.39. Vertex Pharmaceuticals Incorporated has a 12-month low of $320.01 and a 12-month high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.66 by $1.10. The business had revenue of $2.69 billion for the quarter, compared to analyst estimates of $2.58 billion. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The company’s revenue for the quarter was up 13.3% compared to the same quarter last year. During the same quarter last year, the business earned $2.67 earnings per share. As a group, analysts predict that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

VRTX has been the topic of several research analyst reports. Guggenheim boosted their target price on shares of Vertex Pharmaceuticals from $445.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, April 18th. Oppenheimer reissued an “outperform” rating and set a $500.00 price objective on shares of Vertex Pharmaceuticals in a report on Monday, April 15th. Maxim Group lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Cantor Fitzgerald reiterated an “overweight” rating and set a $440.00 price target on shares of Vertex Pharmaceuticals in a research note on Tuesday, February 20th. Finally, Piper Sandler increased their price objective on Vertex Pharmaceuticals from $450.00 to $456.00 and gave the company an “overweight” rating in a report on Tuesday. Three research analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $432.18.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.